E2112—Does a negative phase III trial of endocrine therapy plus histone deacetylase inhibitor in hormone receptor‐positive advanced breast cancer represent a death knell?

Detalles Bibliográficos
Autor principal: Zhang, Liyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058311/
https://www.ncbi.nlm.nih.gov/pubmed/35352486
http://dx.doi.org/10.1111/1759-7714.14399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058311/
https://www.ncbi.nlm.nih.gov/pubmed/35352486
http://dx.doi.org/10.1111/1759-7714.14399

Ejemplares similares